Related Experiment Video

Updated: Jun 6, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Cabazitaxel, a new taxane with favorable properties

B P Bouchet1, C M Galmarini

  • 1Université Lyon 1, ISPB, IFR62, INSERM U590, Centre Léon Bérard, Lyon, France. cgalmarini@pharmamar.com

Drugs of Today (Barcelona, Spain : 1998)
|November 16, 2010
PubMed

Insights

Cabazitaxel offers a new treatment option for advanced cancers, showing effectiveness in taxane-resistant breast and prostate cancers. Clinical trials confirm its survival benefits, particularly in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cabazitaxel is a novel taxane with improved properties over existing treatments.
  • It demonstrates reduced P-glycoprotein (Pgp)-mediated drug resistance.
  • Preclinical studies showed efficacy across various cancer cell lines, including Pgp-expressing tumors.

Purpose of the Study:

  • To evaluate the clinical activity and safety of cabazitaxel.
  • To assess cabazitaxel's efficacy in taxane-resistant metastatic breast cancer and docetaxel-pretreated metastatic castration-resistant prostate cancer.
  • To compare cabazitaxel/prednisone with mitoxantrone/prednisone in the TROPIC phase III trial.

Main Methods:

  • Phase I clinical trials to establish safety and side effect profiles.
  • Clinical studies in patients with taxane-resistant metastatic breast cancer.
  • The TROPIC phase III trial comparing cabazitaxel/prednisone to mitoxantrone/prednisone in men with metastatic castration-resistant prostate cancer.

Main Results:

  • Cabazitaxel exhibits a safety profile similar to other taxanes, with neutropenia and neuropathy as common toxicities.
  • Clinical activity was observed in women with taxane-resistant metastatic breast cancer.
  • The TROPIC trial demonstrated significantly longer overall survival with cabazitaxel/prednisone compared to mitoxantrone/prednisone in men with metastatic castration-resistant prostate cancer.

Conclusions:

  • Cabazitaxel is a clinically active agent with a manageable safety profile.
  • It provides a survival benefit for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
  • Cabazitaxel's efficacy led to its FDA approval in 2010 for this indication.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...